Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Repligen Cp
(NQ:
RGEN
)
158.16
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Repligen Cp
< Previous
1
2
3
4
5
Next >
Silk Road Medical Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
July 22, 2022
Silk Road Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 90.
Via
Investor's Business Daily
Tesla, Danaher And Some Other Big Gainers From Yesterday
July 22, 2022
U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
July 22, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...
Via
Benzinga
Recap: Repligen Q1 Earnings
April 27, 2022
Repligen (NASDAQ:RGEN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
July 21, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending...
Via
Benzinga
Thoughts For Thursday: Which Way Through Uncertainty?
June 30, 2022
Markets are trying to maintain resistance levels generated from last week's rally, but finding the path to doing so is proving to be no easy matter.
Via
Talk Markets
Happy Birthday, iphone!
June 29, 2022
Exactly a decade and a half ago to the day, what is now the staple of the smartphone market first hit the shelves.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance
February 17, 2022
Repligen Corp (NASDAQ: RGEN)
Via
Benzinga
Earnings Scheduled For February 17, 2022
February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Via
Benzinga
Earnings Scheduled For October 28, 2021
October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
July 20, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Thursday
April 28, 2022
Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.
Via
Benzinga
61 Biggest Movers From Yesterday
April 28, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...
Via
Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
April 27, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of...
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Repligen Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 20, 2022
Repligen (NASDAQ:RGEN) will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Repligen (RGEN) Conference Call Follow this link to access the...
Via
Benzinga
Elephant Tracking: How to Spot the Market’s Next Mega Winners BEFORE They Take Off
April 11, 2022
If you follow an elephant's tracks, you find an elephant. If you follow a large money manager, you'll find the winners they've identified.
Via
InvestorPlace
Repligen Earnings Perspective: Return On Capital Employed
February 18, 2022
Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) showed a loss in earnings since Q3, totaling $29.11 million. Sales, on the other hand, increased by 4.66% to $186.52 million during Q4.
Via
Benzinga
Earnings Scheduled For April 27, 2022
April 27, 2022
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 19, 2022
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...
Via
Benzinga
10 Biggest Price Target Changes For Friday
February 18, 2022
Needham lowered Fiverr International Ltd. (NYSE: FVRR) price target from $205 to $100. Fiverr International shares gained 2% to $80.00 in pre-market trading. Wedbush cut the...
Via
Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
This Foreboding Sign Looms Over Repligen's Chart
February 02, 2022
If history is any guide, there may be trouble ahead for shares of Repligen (NASDAQ:RGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Repligen Stock Shows Leadership With 86 RS Rating
December 14, 2021
A RS Rating upgrade for Repligen stock shows improving technical performance for the top-ranked firm in the Medical Products group.
Via
Investor's Business Daily
Repligen Corp (RGEN) Q3 2021 Earnings Call Transcript
October 28, 2021
RGEN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.